[Sequential therapy with methotrexate and 5-fluorouracil in patients with advanced colorectal cancer pretreated with 5-fluorouracil plus folinic acid].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Terapia sequenziale con methotrexate e 5-fluorouracile in pazienti affetti da carcinoma colorettale avanzato pretrattati con 5-fluorouracile + acido folinico.
    • Source:
      Publisher: Societa Editrice Universo Country of Publication: Italy NLM ID: 0372604 Publication Model: Print Cited Medium: Print ISSN: 0009-9074 (Print) Linking ISSN: 00099074 NLM ISO Abbreviation: Clin Ter Subsets: MEDLINE
    • Publication Information:
      Original Publication: Roma : Societa Editrice Universo
    • Subject Terms:
      Colorectal Neoplasms/*pathology ; Fluorouracil/*therapeutic use ; Leucovorin/*therapeutic use ; Methotrexate/*therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Colorectal Neoplasms/drug therapy ; Fluorouracil/toxicity ; Humans ; Leucovorin/toxicity ; Liver Neoplasms/secondary ; Methotrexate/toxicity ; Neoplasm Staging ; Stomatitis/chemically induced
    • Abstract:
      Purpose: To evaluate the efficacy and toxicity of a sequential low-dose methotrexate (MTX) and 5-fluorouracil (5FU) regimen in the palliative treatment of patients with advanced colorectal cancer.
      Patients and Methods: Enrolled in the study were patients with advanced colorectal cancer, refractory to 5FU + FA. Patients were treated with MTX 40 mg/m2 i.v. bolus d 1 and 8, 5FU 700 mg/m2 i.v. bolus d 2 and 9 (24 hours after MTX bolus). The cycle was repeated every 4 weeks.
      Results: 48 patients entered the study, and 45 are evaluable. The overall response rate was 15% with 1 complete response and 6 partial responses. Eight patients obtained disease stabilization. Median time to progression was 9 months. Toxicity was mild. Grade 3 stomatitis was observed in 7 (15%) patients.
      Conclusions: Sequential MTX/5FU is a well tolerated regimen with mild antitumor activity in refractory advanced colorectal patients.
    • Accession Number:
      Q573I9DVLP (Leucovorin)
      U3P01618RT (Fluorouracil)
      YL5FZ2Y5U1 (Methotrexate)
    • Publication Date:
      Date Created: 19981022 Date Completed: 19981105 Latest Revision: 20131121
    • Publication Date:
      20221213
    • Accession Number:
      9780473